Literature DB >> 20484457

The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals.

Iván Hernández-Díaz1, Teresa Giraldez, María Rosa Arnau, Veronique A J Smits, Frederic Jaisser, Nicolette Farman, Diego Alvarez de la Rosa.   

Abstract

The mineralocorticoid receptor (MR), a member of the nuclear receptor family, mediates the action of aldosterone in target epithelia, enhancing sodium reabsorption. In addition, MR may have other physiological functions in nonepithelial tissues. Altered expression or inappropriate activation of cardiac MR is directly linked to the development of cardiac fibrosis, and MR blockade is beneficial for the treatment of heart failure. However, the physiological role, activation status, and target genes of MR in the heart are poorly known. Because ligand-free steroid receptors are typically cytoplasmic and translocate to the nucleus upon ligand binding, we examined the subcellular localization of MR under different corticosteroid levels using subcellular fractionation and immunostaining. Our results demonstrate that MR is a chromatin-bound factor in mouse left ventricle and in a cultured model of cardiomyocytes, HL-1 cells, regardless of circulating corticosteroid levels. Immunohistochemical localization of MR in human heart confirms the subcellular localization pattern. Mutation of nuclear localization signals (NLSs) demonstrates that MR constitutive nuclear localization mainly depends on the synergistic contribution of NLS0 and NLS1. Constitutive nuclear localization in HL-1 cells can be reverted by cotransfection of heat shock protein 90. Heat shock protein 90 expression levels in the mouse heart and HL-1 cells are lower than those found in other tissues, suggesting that low levels of cochaperones render MR NLSs hyperactive in cardiomyocytes. Even though MR is constitutively nuclear, corticosteroids still control the transactivation properties of the receptor in a model promoter, although other MR ligand-independent activities cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484457     DOI: 10.1210/en.2010-0099

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies.

Authors:  Celso E Gomez-Sanchez; Mary Warden; Miriam T Gomez-Sanchez; Xu Hou; Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2011-09-10       Impact factor: 2.668

Review 2.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

3.  Phosphorylation of Mineralocorticoid Receptor Ligand Binding Domain Impairs Receptor Activation and Has a Dominant Negative Effect over Non-phosphorylated Receptors.

Authors:  Rubén Jiménez-Canino; Miguel X Fernandes; Diego Alvarez de la Rosa
Journal:  J Biol Chem       Date:  2016-07-15       Impact factor: 5.157

4.  Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.

Authors:  Yueh-Chun Lee; Wen-Wei Chang; Yi-Ying Chen; Yu-Hung Tsai; Ying-Hsiang Chou; Hsien-Chun Tseng; Hsin-Lin Chen; Chun-Chieh Wu; Ju Chang-Chien; Hsueh-Te Lee; Huei-Fan Yang; Bing-Yen Wang
Journal:  Int J Mol Sci       Date:  2017-09-15       Impact factor: 5.923

5.  Importins involved in the nuclear transportation of steroid hormone receptors: In silico and in vitro data.

Authors:  Konstantina Kalyvianaki; Athanasios A Panagiotopoulos; Maria Patentalaki; Elias Castanas; Marilena Kampa
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.